SWX:GALEHealthcare
Assessing Galenica (SWX:GALE) Valuation After Confirmed 2026 Growth Guidance
Galenica (SWX:GALE) confirmed its 2026 guidance and reiterated expectations for sales growth of 5% to 7% and EBIT growth of 6% to 8%, keeping investor attention on its earnings outlook.
See our latest analysis for Galenica.
The confirmation of 2026 guidance comes after a period where the share price has lost some momentum. The 90 day share price return is down 12.45% and the year to date share price return is down 15.29%, even as the 5 year total shareholder return of 49.84% points to more...